News
Why Exactech Skyrocketed 31% Today
After agreeing to be taken private by global alternative asset manager TPG Capital, Exactech (NASDAQ: EXAC) jumped 31% today.Exactech makes orthopedic implant devices and related surgical....
Fintech Joint Venture Launched: Here's Why Investors Should Take Notice
As the fintech industry matures, more and more companies in this arena are looking to either encroach on traditional banks' territory or figure out ways they can service banks to help usher them....
Why Agenus Inc. Stock Briefly Popped Today
Agenus (NASDAQ: AGEN), a clinical-stage cancer immunotherapy company, saw its shares open up 13% higher Monday on trading volumes nearly six times the daily average. The move came in response to....
A Foolish Take: The Best-Performing S&P 500 Stock This Year
It has been a good year so far for stocks, with the S&P 500 up 15% since the beginning of 2017. But that's just an average of the 500 stocks on the large-cap index; some have done even....
3 Gene Therapy Stocks That Could Make You Rich
The FDA just approved another gene-altering cancer treatment that will save thousands of lives. Yescarta from Gilead Sciences (NASDAQ: GILD) teaches cancer patients' immune cells to seek out and....
3 Things You Should Expect in Gilead Sciences' Q3 Results
Things are looking up for Gilead Sciences (NASDAQ: GILD) for the first time in quite a while. Although the big biotech stock fell in the first half of 2017, its share price is up big since late....
3 Healthcare Stocks for Your Radar
The healthcare sector is one the most exciting and volatile industries out there, with clinical trial results and administrative changes having the potential to make or break so many companies.....
5 Must-Read Quotes for Robotic Surgery Investors
Something big just happened in the robotic surgical industry. Last week, a small company called TransEnterix (NYSEMKT: TRXC) won FDA approval for its Senhance Robotic Surgical System. The....
Should You Avoid Celgene Stock After Its Big Pipeline Setback?
Even some of the biggest and best have things go wrong every now and then. Celgene (NASDAQ: CELG) has been the best-performing biotech stock over the last five years among big biotechs with market....
5 Key Drugs Critical to Johnson & Johnson's Future
Johnson & Johnson (NYSE: JNJ) recently shared its third-quarter financial report card with investors, and by all measures, it deserves kudos. However, the stock market rewards investors based....
Robots Power Profits at Intuitive Surgical
Intuitive Surgical (NASDAQ: ISRG) recently provided investors with its third-quarter financial report card, and the company delivered high marks for system placements and sales and procedure....
Cost-Sharing Reductions: What Are They, and Why It Matters That Trump Is Ending Them
The Affordable Care Act (ACA) was signed into law more than seven years ago, but the fact remains that many Americans still don't understand Barack Obama's hallmark healthcare law, or healthcare....
With Lots of Moving Pieces, Intuitive Surgical, Inc. Reports Yet Another Strong Quarter
Intuitive Surgical (NASDAQ: ISRG) shareholders like myself have gotten spoiled. After some lean years following the onset of the Affordable Care Act and the concurrent tightening of hospitals'....
Intuitive Surgical Continues Its Strong Growth
Intuitive Surgical, Inc. (NASDAQ: ISRG), the leader in robotic-assisted surgery, announced the results of its just-completed third quarter after the market closed on Thursday. The company reported....
How Big of a Deal Is Celgene's Flop?
Celgene (NASDAQ: CELG) shuttered two GED-301 Crohn's disease trials this week after an interim look at data by independent monitors proved disappointing. The late-stage failure dings Celgene's....
Why Celgene Corporation Dropped Today
Celgene (NASDAQ: CELG) is down 10.2% at 12:09 p.m. Friday after announcing yesterday after the market closed that it was stopping a clinical trial testing GED-0301 (mongersen) in Crohn's disease....
3 High-Yield Pharmaceutical Stocks
Pharmaceutical stocks are generally an outstanding place to look for sustainable sources of passive income. Even though most companies offer fairly modest yields due to the costly nature of....
Celgene Could Be the Best CAR-T Stock to Buy, Not Gilead Sciences
Gilead Sciences' (NASDAQ: GILD) recently approved Yescarta could be a billion-dollar blockbuster cancer-cell therapy, but the company could face stiff competition from Celgene (NASDAQ:....
Gilead Slaps Mega-Price on Its Newly Approved CAR-T
Gilead Sciences (NASDAQ: GILD) recently acquired clinical-stage CAR-T drugmaker Kite Pharma, for $11.9 billion and on Wednesday, the FDA helped validate the company's purchase price by approving....
Why TransEnterix Stock Tanked Today
Shares of TransEnterix (NYSEMKT: TRXC), an early commercial-stage robotic surgery company, ended today's trading session down another 16.4%. The company's shares have now given back a healthy....
Abbott Laboratories Q3 2017 Earnings Conference Call Transcript (ABT)
Abbott Laboratories (NYSE: ABT)Image source: The Motley Fool.Q3 2017 Earnings Conference CallOct. 18, 2017, 9:00 a.m. ET Continue readingSource: Fool.com
3 High-Yield Stocks for Conservative Investors
Conservative equates to cautious. We're talking investing here, of course, and not politics. Conservative investors are by nature cautious. There's nothing wrong with that. After all, Warren....
3 Things to Expect in Illumina's Q3 Earnings Results
A quick look at Illumina (NASDAQ: ILMN) stock's performance is all you need to know how the company's first two quarters in 2017 went. Illumina's share price has soared 60% so far this year after....
Why SUPERVALU, Synchronoss Technologies, and Allergan Slumped Today
Wednesday was generally a good day for the stock market, with major benchmarks posting solid gains. Broad measures like the S&P 500 and the Nasdaq Composite were up just modestly from....
Here's Why Ignyta Stock Soared as Much as 27.5% Today
Shares of pre-revenue biopharma Ignyta (NASDAQ: RXDX) jumped over 27% Wednesday morning after it announced promising interim results from an ongoing phase 2/3 clinical trial investigating the....